Johnson & Johnson (NYSE:JNJ) Shares Up 3.3% – What’s Next?

Johnson & Johnson (NYSE:JNJ) shares traded up 3.3% during mid-day trading on Tuesday . The stock traded as high as $271.73 and last traded at $271.0480. Approximately 7,824,211 shares traded hands during mid-day trading, a decline of 5% from the average daily volume of 8,270,486 shares. The stock had previously closed at $262.37.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA clearance strengthens the MedTech outlook. Johnson & Johnson received FDA clearance for the AI-powered MONARCH QUEST 3 bronchoscopy system. The software adds AI-assisted planning, improved navigation and expanded imaging capabilities, supporting broader use of the MONARCH platform in lung diagnostics. J&J secures FDA clearance for MONARCH QUEST 3 bronchoscopy system
• Positive Sentiment: Robotic surgery momentum is adding to investor enthusiasm. The regulatory progress for MONARCH QUEST 3 follows FDA authorization for J&J’s OTTAVA robotic surgical system, reinforcing the company’s strategy to build higher-growth businesses beyond pharmaceuticals. Why Johnson & Johnson stock is up today
• Positive Sentiment: Immunology and neuroscience are emerging as growth engines. New products in these areas are helping offset the loss of exclusivity for Stelara, easing concerns about the pharmaceutical portfolio’s longer-term growth. J&J’s new growth powerhouses
• Positive Sentiment: Recent operating results provide fundamental support. J&J’s latest quarterly revenue rose 6.6% year over year to $25.31 billion, while adjusted earnings exceeded estimates. Management also set 2026 adjusted EPS guidance of $11.60 to $11.75.
• Neutral Sentiment: Options activity indicates heightened bullish interest. Traders purchased 34,603 call options, about 29% above average call volume, although options activity alone does not guarantee continued gains.
• Negative Sentiment: Insider selling remains a risk signal. Company insiders reported 21 open-market sales and no purchases during the past six months. Analyst targets are mixed, with a recent median target of $263, potentially limiting upside after the recent advance.

Analyst Ratings Changes

A number of equities analysts have weighed in on JNJ shares. Guggenheim increased their price target on shares of Johnson & Johnson from $270.00 to $287.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a report on Monday, August 3rd. HSBC set a $290.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday, July 6th. Argus set a $300.00 target price on Johnson & Johnson in a report on Wednesday, July 29th. Finally, Citigroup boosted their price target on Johnson & Johnson from $285.00 to $298.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $268.22.

Johnson & Johnson Trading Up 3.3%

The firm’s 50 day simple moving average is $252.52 and its 200-day simple moving average is $241.60. The company has a market capitalization of $653.20 billion, a PE ratio of 31.41, a P/E/G ratio of 2.48 and a beta of 0.24. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.11%.

Insiders Place Their Bets

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the firm’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,779,963.81. This trade represents a 50.06% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 48,972 shares of company stock worth $12,295,205 over the last quarter. 0.16% of the stock is owned by corporate insiders.

Institutional Trading of Johnson & Johnson

Hedge funds have recently made changes to their positions in the company. Auto Owners Insurance Co boosted its stake in shares of Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after purchasing an additional 69,108,368 shares during the period. Norges Bank acquired a new position in Johnson & Johnson in the 4th quarter worth $6,924,523,000. Capital World Investors purchased a new position in Johnson & Johnson in the 4th quarter valued at about $2,005,942,000. Jupiter Topco LLC purchased a new position in Johnson & Johnson in the 2nd quarter valued at about $1,967,399,000. Finally, Diamant Asset Management Inc. grew its stake in shares of Johnson & Johnson by 24,436.5% during the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock valued at $109,338,000 after acquiring an additional 4,454,778 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.